ClearPoint Neuro, Inc.
NASDAQ•CLPT
CEO: Mr. Joseph Michael Burnett
板块: Healthcare
行业: Medical - Devices
上市日期: 2012-05-22
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
联系方式
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, 92075, United States
888-287-9109
市值
$312.36M
市盈率 (TTM)
-11.6
23.8
股息率
--
52周最高
$30.10
52周最低
$8.27
52周范围
排名55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
基于 10 年期基本面
疲弱 • 2.6 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2016-2025
财务仪表盘
Q4 2025 数据
营业收入
$10.41M+0.00%
近4季度走势
每股收益
-$0.27+0.00%
近4季度走势
自由现金流
-$12.13M+0.00%
近4季度走势
2025 Annual 财报亮点
核心亮点
Total Revenue Rises 18% Total revenue reached $37.0M USD, marking an 18% increase driven by product sales growth across segments.
Product Sales Surge 28% Product revenue grew 28% to $23.9M USD; neurosurgery disposable sales increased 44% year-over-year.
IRRAS Acquisition Closed Completed IRRAS acquisition in Q4 2025, expanding portfolio into neurocritical care with IRRAflow system integration.
Gross Margin Remains Stable Gross profit reached $22.7M USD; gross margin held steady at 61% despite increased operating costs.
关注风险
Net Loss Widens Significantly Net loss increased 35% to $(25.5M) USD in 2025; sustained profitability remains uncertain given ongoing investments.
High Customer Revenue Concentration Significant customer concentration risk exists; top five hospital customers accounted for 21% of 2025 disposable revenues.
Operating Expenses Increase General and administrative expenses rose 38% to $16.5M USD, driven by IRRAS acquisition integration costs.
Market Adoption Uncertainty Future growth hinges on achieving broad market adoption for ClearPoint and IRRAflow systems against established competitors.
前瞻展望
Anticipated Future Funding Needs Expect need for additional capital following IRRAS acquisition to fund commercialization and integration efforts through 2026.
Expand Installed Base Future objectives depend on expanding installed base and procedure volumes for both ClearPoint and IRRAflow platforms.
Biologics Partner Pipeline Over 60 partners evaluate products for gene/cell therapy delivery; success depends on partner clinical trial outcomes.
Cybersecurity Integration Planned Expect to fully integrate IRRAS cybersecurity governance structure and risk management framework throughout 2026.
同行对比
营业收入 (TTM)
$912.10M
$854.40M
$824.50M
毛利率 (最新季度)
83.5%
79.0%
78.8%
关键指标
股票代码 | 市值 | 市盈率 (TTM) | 净资产收益率 (TTM) | 负债率 |
|---|---|---|---|---|
| AXGN | $1.94B | -111.7 | -13.4% | 8.7% |
| TYRA | $1.89B | -17.5 | -41.2% | 2.1% |
| OLMA | $1.44B | -9.3 | -42.9% | 0.2% |
长期趋势
近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
7.1%
稳定增长
4季度净利润复合增长率
N/M
盈利状态转变
现金流稳定性
0%
现金流需要关注
深度研究
下次财报:2026年5月11日
每股收益:-
|营业收入:-
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表 | 过去12个月 |
|---|
无数据